India's Aurobindo has recalled a lot of an epilepsy drug because some of the capsules contain no drug at all.
A U.S. oncologist who thought he was getting a great deal on drugs that were almost the same thing as Avastin has found they will cost him an extra $2 million and a federal misdemeanor conviction.
Trying hard to fight off a hostile takeover by Canada's Valeant, Botox maker Allergan has sent out press releases every time it stumbles onto something that appears to besmirch its pursuer. New fodder is in this week's FDA Enforcement Report. Valeant is recalling a couple hundred thousand bottles and tubes of products.
More than three dozen drugs and APIs that were originally banned by health regulators in Canada will be allowed into the country because they are medically necessary.
Not all drug recalls track back to quality issues during manufacturing. A glitch in the supply chain can also come into play, and that is what happened with a lot of vancomycin hydrochloride injection being recalled by Hospira.
The Indian government has begun legal action against think tank the American Enterprise Institute (AEI) over a paper on drug quality, The Times of India reports.
The three-way spat between Health Canada, local media and Apotex is rumbling on. Late last week Health Canada won an equivocal thumbs-up from the media for its move to quarantine products from one of Apotex's Indian plants, only for the generic drugmaker to hit back with a press release to "set the record straight."
The problem of contaminated cold remedies has once again surfaced in the U.S. More than seven years after diethylene glycol put authorities on high alert, a toddler in New York has suffered from lead poisoning after taking a Chinese cold remedy.
Impax Laboratories has enough on its plate trying to get its manufacturing facilities in tip-top shape ahead of FDA reconsideration of its Parkinson drug, which was sidelined over the issues. A securities lawsuit tied to those manufacturing setbacks was a distraction it didn't need, and so it has settled the litigation.
Mylan and Health Canada have rethought a recall of Mylan-Nitro Spray that it hopes will not deprive users of the meds they need for angina. The effort comes as the FDA has been fighting a shortage of nitroglycerin in the U.S.